Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.94 USD
-0.02 (-1.96%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.94 0.00 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KPTI 0.94 -0.02(-1.96%)
Will KPTI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPTI
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Other News for KPTI
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm price target lowered by $1 at H.C. Wainwright, here's why
Karyopharm Therapeutics (KPTI) Receives a Buy from RBC Capital
Hold Rating on Karyopharm Amid Competitive Landscape and Pending Data Outcomes
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)